{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:36:37Z","timestamp":1768257397514,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["IME-GBR-15474"],"award-info":[{"award-number":["IME-GBR-15474"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Variable disease progression confounds accurate prognosis in Fabry disease. Evidence supports the long-term benefit of early intervention with disease-specific therapy, but current guidelines recommend treatment initiation based on signs that may present too late to avoid irreversible organ damage. Findings from the \u2018PRoposing Early Disease Indicators for Clinical Tracking in Fabry Disease\u2019 (PREDICT-FD) initiative included expert consensus on 27 early indicators of disease progression in Fabry disease and on drivers of and barriers to treatment initiation in Fabry disease. Here, we compared the PREDICT-FD indicators with guidance from the European Fabry Working Group and various national guidelines to identify differences in signs supporting treatment initiation and how guidelines themselves might affect initiation. Finally, anonymized patient histories were reviewed by PREDICT-FD experts to determine whether PREDICT-FD indicators supported earlier treatment than existing guidance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Current guidelines generally aligned with PREDICT-FD on indicators of renal involvement, but most lacked specificity regarding cardiac indicators. The prognostic significance of neurological indicators such as white matter lesions (excluded by PREDICT-FD) was questioned in some guidelines and excluded from most. Some PREDICT-FD patient-reported signs (e.g., febrile crises) did not feature elsewhere. Key drivers of treatment initiation in PREDICT-FD were: (A) male sex, young age, and clinical findings (e.g., severe pain, organ involvement), (B) improving clinical outcomes and preventing disease progression, and (C) a family history of Fabry disease (especially if outcomes were severe). All guidelines aligned with (A) and several advocated therapy for asymptomatic male patients. There was scant evidence of (B) in current guidance: for example, no countries mandated ancillary symptomatic therapy, and no guidance advocated familial screening with (C) when diagnosis was confirmed. Barriers were misdiagnosis and a lack of biomarkers to inform timing of treatment. Review of patient histories generally found equal or greater support for treatment initiation with PREDICT-FD indicators than with other guidelines and revealed that the same case and guideline criteria often yielded different treatment recommendations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Wider adoption of PREDICT-FD indicators at a national level could promote earlier treatment in Fabry disease. Clearer, more concise guidance is needed to harmonize treatment initiation in Fabry disease internationally.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02181-4","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T11:05:08Z","timestamp":1644318308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-9173","authenticated-orcid":false,"given":"Derralynn A.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcio","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojan","family":"Vujkovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"2181_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngrimsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"key":"2181_CR2","doi-asserted-by":"crossref","unstructured":"Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts J, Artola M. Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules. 2021;11(2).","DOI":"10.3390\/biom11020271"},{"issue":"1","key":"2181_CR3","first-page":"37","volume":"5","author":"C Ellaway","year":"2016","unstructured":"Ellaway C. Paediatric Fabry disease. Transl Pediatr. 2016;5(1):37\u201342.","journal-title":"Transl Pediatr"},{"issue":"11","key":"2181_CR4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750\u201360.","journal-title":"J Med Genet"},{"issue":"11","key":"2181_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769\u201375.","journal-title":"J Med Genet"},{"key":"2181_CR6","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Pastores GM, Lien YH, Castaneda V, Chang P, Martin R et al. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study. Orphanet J Rare Dis. 2014;9:169.","DOI":"10.1186\/s13023-014-0169-6"},{"key":"2181_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/8904_2014_310","volume":"16","author":"J Politei","year":"2014","unstructured":"Politei J, Amartino H, Schenone AB, Cabrera G, Michref A, Tanus E, et al. Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta. JIMD Rep. 2014;16:7\u201314.","journal-title":"JIMD Rep"},{"issue":"4","key":"2181_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/HCO.0000000000000308","volume":"31","author":"DA Hughes","year":"2016","unstructured":"Hughes DA. Fabry disease: will markers of early disease enable early treatment and better outcomes? Curr Opin Cardiol. 2016;31(4):434\u20139.","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"2181_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","volume":"121","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017;121(2):157\u201361.","journal-title":"Mol Genet Metab"},{"key":"2181_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2020-107338","author":"A Nowak","year":"2021","unstructured":"Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet. 2021. https:\/\/doi.org\/10.1136\/jmedgenet-2020-107338.","journal-title":"J Med Genet"},{"key":"2181_CR11","doi-asserted-by":"crossref","unstructured":"Hughes DA, Aguiar P, Deegan PB, Ezgu F, Frustaci A, Lidove O et al. Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open. 2020;10(10):e035182.","DOI":"10.1136\/bmjopen-2019-035182"},{"key":"2181_CR12","unstructured":"Replagal SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf. Accessed Mar 30 2021."},{"key":"2181_CR13","unstructured":"REPLAGAL\u00ae (agalsidase alfa ghu) Australian product information\u2014November 2020. http:\/\/www.guildlink.com.au\/gc\/ws\/tk\/pi.cfm?product=tkprepla10118. Accessed Aug 24 2021."},{"key":"2181_CR14","unstructured":"FABRAZYME (AGALSIDASE BETA - RCH) Australian product information\u2014July 2020. http:\/\/www.guildlink.com.au\/gc\/ws\/sw\/pi.cfm?product=swpfabra10620. Accessed Aug 24 2021."},{"key":"2181_CR15","unstructured":"Fabrazyme SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabrazyme-epar-product-information_en.pdf. Accessed Mar 30 2021."},{"key":"2181_CR16","unstructured":"Fabrazyme prescribing information\u2014May 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103979s5135lbl.pdf . Accessed Mar 30 2021."},{"key":"2181_CR17","unstructured":"Amicus announces approval for Galafold (migalastat) for treatment of Fabry disease in Australia. https:\/\/www.biospace.com\/article\/releases\/amicus-announces-approval-for-galafold-migalastat-for-treatment-of-fabry-disease-in-australia-\/. Accessed Aug 24 2021."},{"key":"2181_CR18","unstructured":"Galafold SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/galafold-epar-product-information_en.pdf. Accessed Mar 30 2021."},{"key":"2181_CR19","unstructured":"Galafold prescribing information\u2014August 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208623lbl.pdf. Accessed Mar 30 2021."},{"issue":"4","key":"2181_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2020","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep. 2020;5(4):407\u201313.","journal-title":"Kidney Int Rep"},{"key":"2181_CR21","unstructured":"Canadian Fabry Disease Treatment Guidelines. https:\/\/garrod.ca\/wp-content\/uploads\/2020\/02\/Canadian-Fabry-Treatment-Guidelines-2019-final.pdf. Accessed Aug 25 2021."},{"key":"2181_CR22","unstructured":"[Specific therapy for Fabry disease]. http:\/\/www.insa.min-saude.pt\/wp-content\/uploads\/2019\/06\/TerapeuticaDoencaFabry.pdf. Accessed Aug 24 2021."},{"key":"2181_CR23","unstructured":"Maladie de Fabry \u2013 Protocole national de diagnostic et de soins [Fabry disease \u2013 National Diagnostic and Care Protocol]. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2010-12\/ald_17_pnds_fabry_vd.pdf. Accessed Aug 25 2021."},{"key":"2181_CR24","unstructured":"Life Saving Drugs Program \u2013 Fabry disease \u2013 Guidelines \u2013 October 7, 2020. https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2020\/11\/life-saving-drugs-program-fabry-disease-guidelines.pdf. Accessed Aug 24 2021."},{"key":"2181_CR25","doi-asserted-by":"crossref","unstructured":"Lidove O, Bekri S, Goizet C, Khau Van Kien A, Aractingi S, Knebelmann B et al. Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up. Presse Med. 2007;36(7\u20138):1084\u201397.","DOI":"10.1016\/j.lpm.2007.01.006"},{"key":"2181_CR26","unstructured":"Guidelines for the treatment of Fabry Disease. http:\/\/www.bimdg.org.uk\/store\/lsd\/\/FabryGuide_LSDSS_Jan2020_700523_11032020.pdf. Accessed Aug 25 2021."},{"issue":"9","key":"2181_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"11","key":"2181_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/adc.51.11.875","volume":"51","author":"R Counahan","year":"1976","unstructured":"Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child. 1976;51(11):875\u20138.","journal-title":"Arch Dis Child"},{"issue":"12","key":"2181_CR29","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3390\/ijms17121965","volume":"17","author":"MA Barba-Romero","year":"2016","unstructured":"Barba-Romero MA, Pintos-Morell G. Gender differences in the application of Spanish criteria for initiation of enzyme replacement therapy for Fabry disease in the Fabry outcome survey. Int J Mol Sci. 2016;17(12):1965.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"2181_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.medcli.2018.10.039","volume":"153","author":"MA Barba-Romero","year":"2019","unstructured":"Barba-Romero MA, Serena J, Puig JM, Valverde CV, Climent V, Herrero JA, et al. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy. Med Clin (Barc). 2019;153(2):47\u201355.","journal-title":"Med Clin (Barc)"},{"key":"2181_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cca.2020.02.006","volume":"505","author":"J Hedley","year":"2020","unstructured":"Hedley J, Menon V, Cho L, McShane AJ. Fifth generation troponin T assay is subject to antibody interference. Clin Chim Acta. 2020;505:98\u20139.","journal-title":"Clin Chim Acta"},{"key":"2181_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajem.2020.12.051","volume":"41","author":"T Kansara","year":"2021","unstructured":"Kansara T, Majmundar M, Basman C, Visco F. Problems with interpreting troponins in chronic kidney disease patients for ruling out acute coronary syndrome. Am J Emerg Med. 2021;41:14\u20135.","journal-title":"Am J Emerg Med"},{"key":"2181_CR33","doi-asserted-by":"crossref","unstructured":"Hajjari J, Janus SE, Albar Z, Al-Kindi SG. Myocardial injury and the risk of stroke in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort study). Angiology. 2021:33197211005595.","DOI":"10.1177\/00033197211005595"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02181-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T11:18:50Z","timestamp":1644319130000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02181-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02181-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"assertion":[{"value":"24 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No patient-level data are reported in this study and no ethical approval was sought.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DAH: advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); consulting fees from Amicus Therapeutics, Idorsia Pharmaceuticals, Sanofi, and Shire (now part of Takeda); fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda). PA: research grant and fees from Shire (now part of Takeda); fees from Amicus Therapeutics, BioMarin Pharmaceutical, Sanofi, and Ultragenyx Pharmaceutical. OL: travel grants and speaker fees from Amicus Therapeutics, Sanofi Genzyme, and Shire HGT. KN: research support and\/or fees from Amicus Therapeutics, Idorsia Pharmaceuticals, Protalix Biotherapeutics, Sanofi, and Shire (now part of Takeda); advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda). AN: fees and research support from Amicus Therapeutics, Sanofi Genzyme, and Shire (now part of Takeda). MT: advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); travel grants and speaker fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); research funding from 4D Molecular Therapeutics, Amicus Therapeutics, AVROBIO, and Idorsia Pharmaceuticals. RTB: travel grants, speaker fees, or consultation fees from Amicus, Sanofi Genzyme, and Takeda. BV: speaker fees and travel support from Greenovation, Sanofi Genzyme, and Shire (now part of Takeda); advisory board fees from Sanofi Genzyme. MLW: advisory boards for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); research funding from Amicus Therapeutics, Idorisia Pharmaceuticals, Protalix Biotherapeutics, and Shire (now part of Takeda). SF: advisory boards for Amicus Therapeutics; consulting fees from Shire (now part of Takeda); contracted research from Shire (now part of Takeda); fees from Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); speakers bureaux for Amicus Therapeutics, Sanofi, and Shire (now part of Takeda); travel expenses from Amicus, Sanofi and Shire (now part of Takeda).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}